Price4.35%   -0.0836

Spero Therapeutics (SPRO) Stock Discussions on Social Media

- SPRO Stock on Twitter: https://twitter.com/search?q=$spro
- SPRO Stock on Reddit: https://www.reddit.com/search/?q=$spro
- SPRO Stock on SeekingAlpha: https://seekingalpha.com/symbol/SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):